{"product_id":"asco-genitourinary-cancers-symposium","title":"ASCO Genitourinary Cancers Symposium 2025 (Videos + Slides + Posters)","description":"\u003ch3\u003eProgram\u003c\/h3\u003e\u003cbr\u003eThe 2025 ASCO Genitourinary Cancers Symposium will provide expert, multidisciplinary perspectives on the latest clinical and scientific advances in the field. View the official \u003cstrong\u003eMeeting Announcement\u003c\/strong\u003e for a message from the Chair, Program Highlights, Featured Sessions information, and how to register.\u003cbr\u003e\u003ch3\u003eProgram At A Glance\u003c\/h3\u003e\n\u003ch3\u003eThursday, February 13, 2025\u003c\/h3\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:00 AM-\u003cbr\u003e8:00 AM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eComplimentary Continental Breakfast\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:00 AM-\u003cbr\u003e6:45 AM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eExhibits Open\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:00 AM-\u003cbr\u003e9:40 AM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOral Abstract Session A: Prostate Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eKosj Yamoah, MD, PhD—Chair\u003c\/strong\u003e\u003cbr\u003eH. Lee Moffitt Cancer Center and Research Institute\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eChanning Judith Paller, MD—Chair\u003c\/strong\u003e\u003cbr\u003eThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003ePeter Hoskin, MD, FRCP, FRCR\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWelcome of the Day\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 308:\u003c\/strong\u003e Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.\u003cbr\u003eFirst Author: \u003cstrong\u003eShuang Zhao, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 309:\u003c\/strong\u003e Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).\u003cbr\u003eFirst Author: \u003cstrong\u003eSoumyajit Roy, MBBS\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eEdwin Posadas, MD, FACP\u003c\/strong\u003e\u003cbr\u003eCedars-Sinai Medical Center\u003cbr\u003e\u003cem\u003eDiscussion\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT LBA18\u003c\/strong\u003e: Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.\u003cbr\u003eFirst Author: \u003cstrong\u003eNeeraj Agarwal, MD, FASCO\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 20:\u003c\/strong\u003e Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).\u003cbr\u003eFirst Author: \u003cstrong\u003eDavid John Fisher, MSc\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTanya B. Dorff, MD\u003c\/strong\u003e\u003cbr\u003eCity of Hope Comprehensive Cancer Center\u003cbr\u003e\u003cem\u003eDiscussion\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9:40 AM-10:10 AM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBreak\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:10 AM-11:25 AM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eUnderstanding Radioligand Therapies for Advanced Prostate Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eAngela Y Jia, MD, PhD—Chair\u003c\/strong\u003e\u003cbr\u003eUniversity Hospitals Seidman Cancer Center and Case Western Reserve University\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eDevaki Shilpa Surasi, MBBS—Chair\u003c\/strong\u003e\u003cbr\u003eUniversity of Texas at MD Anderson Cancer Center\u003cbr\u003e\u003cem\u003ePSMA-Based Therapy in Advanced Disease: Touching on Combination Sequencing\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eWilliam Kevin Kelly, DO\u003c\/strong\u003e\u003cbr\u003eThomas Jefferson University Hospital\u003cbr\u003e\u003cem\u003eBeyond PSMA-Targeted Agents for Advanced Disease\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eDanny Mena Cortes\u003c\/strong\u003e\u003cbr\u003eNuclear Medicine World\u003cbr\u003e\u003cem\u003eSeeing Is Believing: Radiographic Criteria to Assess Response\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 17:\u003c\/strong\u003e Overall survival and quality of life with [\u003csup\u003e177\u003c\/sup\u003eLu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).\u003cbr\u003eFirst Author: \u003cstrong\u003eLouise Emmett, MD, FRACP, MBChB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 16: \u003c\/strong\u003eAssociation of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of \u003csup\u003e177\u003c\/sup\u003eLu-PSMA-617.\u003cbr\u003eFirst Author: \u003cstrong\u003eJohann S. De Bono, MD, PhD, MB, FRCP\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:25 AM-12:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePoster Session A: Prostate Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Boxed Lunch\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:25 AM-12:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTrials in Progress Poster Session A: Prostate Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Boxed Lunch\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:35 AM-12:35 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTrainee and Early-Career Networking Luncheon\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eView the networking faculty list\u003cstrong\u003e \u003cem\u003e\u003ca data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"86e3556e-09bd-46aa-ac12-97b30b57a775\" href=\"https:\/\/conferences.asco.org\/gu\/onsite-connections\" title=\"Onsite Connections\"\u003ehere\u003c\/a\u003e\u003c\/em\u003e\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12:45 PM-2:00 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eCase-Based Session: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eMichael Cookson, MD, MMHC, FACS—Chair\u003c\/strong\u003e\u003cbr\u003eUniversity of Oklahoma College of Medicine\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eBarbara Jereczek-Fossa, MD—Chair\u003c\/strong\u003e\u003cbr\u003eIEO European Institute of Oncology IRCCS\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eMichael Cookson, MD, MMHC, FACS\u003c\/strong\u003e\u003cbr\u003eUniversity of Oklahoma College of Medicine\u003cbr\u003e\u003cem\u003eRecurrence After Radiation Therapy: Evaluation, Management, and Outcomes\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eHeather H. Cheng, MD, PhD\u003c\/strong\u003e\u003cbr\u003eUniversity of Washington\u003cbr\u003e\u003cem\u003eMedical Oncology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eJuanita Crook, FRCPC\u003c\/strong\u003e\u003cbr\u003eThe University of British Columbia\u003cbr\u003e\u003cem\u003eRadiation Oncology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eThomas Polascik, MD\u003c\/strong\u003e\u003cbr\u003eDuke University Division of Urologic Surgery\u003cbr\u003e\u003cem\u003eUrology (Ablative Focal)\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eAshley Ross, MD, PhD\u003c\/strong\u003e\u003cbr\u003eNorthwestern University Feinberg School of Medicine\u003cbr\u003e\u003cem\u003eUrology (Salvage Surgery)\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eAlicia K. Morgans, MD, MPH, FASCO\u003c\/strong\u003e\u003cbr\u003eDana-Farber Cancer Institute\u003cbr\u003e\u003cem\u003eThe Impact of Salvage Therapies: Functional Outcomes and Quality of Life\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2:15 PM-3:05 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eKeynote\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003ePeter Hoskin, MD, FRCP, FRCR - Chair\u003c\/strong\u003e\u003cbr\u003eMount Vernon Cancer Centre, University College London, and University of Manchester\u003cbr\u003e\u003cem\u003eIntroduction of Dr. Dahut\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eWilliam L. Dahut, MD\u003c\/strong\u003e\u003cbr\u003eAmerican Cancer Society\u003cbr\u003e\u003cem\u003eCreative Innovation: Driving Science to Improve Patient-Centered Care\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003eQuestion and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3:05 PM-\u003cbr\u003e3:30 PM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBreak\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3:30 PM-\u003cbr\u003e4:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eCase-Based Session: Evolving Landscape of the Management of Oligometastatic Disease\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eKaren E. Hoffman, MD, MHSc, MPH—Chair\u003c\/strong\u003e\u003cbr\u003eThe University of Texas MD Anderson Cancer Center\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eNicholas David James—Chair\u003c\/strong\u003e\u003cbr\u003eInstitute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eABSTRACT 15:\u003c\/strong\u003e World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.\u003cbr\u003eFirst Author: \u003cstrong\u003eChad Tang, MD, BS, MS\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eKenneth L. Gage, MD, PhD\u003c\/strong\u003e\u003cbr\u003eH. Lee Moffitt Cancer Center and Research Institute\u003cbr\u003e\u003cem\u003eRadiology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eBrandon A. Mahal, MD\u003c\/strong\u003e\u003cbr\u003eUniversity of Miami\u003cbr\u003e\u003cem\u003eRadiation Oncology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eKasmintan A. Schrader, PhD, MBBS\u003c\/strong\u003e\u003cbr\u003eBC Cancer\u003cbr\u003e\u003cem\u003eGenetics\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eSandy Srinivas, MD\u003c\/strong\u003e\u003cbr\u003eStanford School of Medicine\u003cbr\u003e\u003cem\u003eMedical Oncology\u003c\/em\u003e\u003cbr\u003e\u003cbr\u003ePanel Question and Answer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5:00 PM-\u003cbr\u003e5:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRapid Oral Abstract Session A: Prostate Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eMarjory Jolicoeur, MD, PhD, FRCPC—Chair\u003c\/strong\u003e\u003cbr\u003eHôpital Charles-LeMoyne\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eABSTRACT 310:\u003c\/strong\u003e Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial. - 5 minutes\u003cbr\u003eFirst Author: \u003cstrong\u003eAbdenour Nabid, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 311:\u003c\/strong\u003e Gut health and prostate cancer: The influence of a specific phytochemical-rich food capsule plus or minus a probiotic\/prebiotic blend on symptoms and progression—A randomised, double-blind placebo-controlled trial. - 5 minutes\u003cbr\u003eFirst Author: \u003cstrong\u003eRobert J. Thomas, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 312:\u003c\/strong\u003e A high omega-3, low omega-6 diet with fish oil for men with prostate cancer on active surveillance: The CAPFISH-3 randomized clinical trial. - 5 minutes\u003cbr\u003eFirst Author: \u003cstrong\u003eWilliam Aronson, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 21:\u003c\/strong\u003e Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform. - 5 minutes\u003cbr\u003eFirst Author: \u003cstrong\u003eNicholas David James, PhD, FRCP, MBBS\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 22:\u003c\/strong\u003e Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9). - 5 minutes\u003cbr\u003eFirst Author: \u003cstrong\u003eTamim Niazi, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT LBA138:\u003c\/strong\u003e Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study. - 5 minutes\u003cbr\u003eFirst Author: \u003cstrong\u003eMichael Thomas Schweizer, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5:45 PM-6:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePoster Session A (Continued)\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Wine and Cheese Reception\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5:45 PM-6:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTrials in Progress Poster Session A (Continued)\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Wine and Cheese Reception\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e6:00 PM-6:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePoster Walks: Prostate Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eMarjory Jolicoeur, MD, PhD, FRCPC\u003c\/strong\u003e\u003cbr\u003eHôpital Charles-LeMoyne\u003cbr\u003e\u003cem\u003ePoster Walk Leader\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eChanning Judith Paller, MD\u003c\/strong\u003e\u003cbr\u003eThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\u003cbr\u003e\u003cem\u003ePoster Walk Leader\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e6:00 PM-\u003cbr\u003e6:45 PM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWomen's Networking Reception\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003cbr\u003e\n\u003c\/table\u003e\n\u003ch3\u003eFriday, February 14, 2025\u003c\/h3\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:00 AM-8:10 AM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eComplimentary Continental Breakfast\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:00 AM-5:45 PM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eExhibits Open\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:10 AM-9:45 AM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOral Abstract Session B: Urothelial Carcinoma\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eElizabeth A. Guancial, MD—Chair\u003c\/strong\u003e\u003cbr\u003eFlorida Cancer Specialists \u0026amp; Research Institute\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eNicholas I. Simon, MD, MSc—Chair\u003c\/strong\u003e\u003cbr\u003eNational Cancer Institute\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eAndrea B Apolo, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWelcome of the Day\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 658: \u003c\/strong\u003eAdjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.\u003cbr\u003eFirst Author: \u003cstrong\u003eMatthew I. Milowsky, MD, FASCO\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 659:\u003c\/strong\u003e Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. - 10 minutes\u003cbr\u003eFirst Author: \u003cstrong\u003eMatthew D. Galsky, MD, FASCO\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eElizabeth R. Plimack, MD, FASCO, MS\u003c\/strong\u003e\u003cbr\u003eFox Chase Cancer Center, Temple Health\u003cbr\u003e\u003cem\u003eDiscussion\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 661:\u003c\/strong\u003e Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine\/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma. - 10 minutes\u003cbr\u003eFirst Author: \u003cstrong\u003eNadine Houede, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 665:\u003c\/strong\u003e Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. - 10 minutes\u003cbr\u003eFirst Author: \u003cstrong\u003eXinan Sheng, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eScot Anthony Niglio, MD, MS\u003c\/strong\u003e\u003cbr\u003eNational Institutes of Health Division of Occupational Health and Safety\u003cbr\u003e\u003cem\u003eDiscussion\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9:45 AM-10:15 AM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBreak\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:15 AM-11:30 AM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eCase-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-Guérin\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eBrian Christopher Baumann, MD—Chair\u003c\/strong\u003e\u003cbr\u003eSpringfield Clinic\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eBogdana Schmidt, MD, MPH—Chair\u003c\/strong\u003e\u003cbr\u003eUniversity of Utah\u003cbr\u003e\u003cem\u003eThe Changing World of Non-Muscle Invasive Bladder Cancer\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003eCase Presentation\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eGirish S. Kulkarni, MD, PhD\u003c\/strong\u003e\u003cbr\u003eDepartment of Surgical Oncology, Princess Margaret Cancer Center, University Health Network\u003cbr\u003e\u003cem\u003eUrology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eMark Tyson, MPH\u003c\/strong\u003e\u003cbr\u003eMayo Clinic Arizona\u003cbr\u003e\u003cem\u003eUrology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eTracy L Rose, MD\u003c\/strong\u003e\u003cbr\u003eUniversity of North Carolina at Chapel Hill\u003cbr\u003e\u003cem\u003eMedical Oncology\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:30 AM-12:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePoster Session B: Urothelial Carcinoma\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Boxed Lunch\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:30 AM-12:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTrials in Progress Poster Session B: Urothelial Carcinoma\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Boxed Lunch\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:40 AM-12:35 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBreakout Session: Emerging Trends and Advances in Germ Cell Tumors\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eAditya Bagrodia, MD—Chair\u003c\/strong\u003e\u003cbr\u003eUniversity of California, San Diego Health\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eAnja Lorch, MD—Chair\u003c\/strong\u003e\u003cbr\u003eUniversitätsspital Zürich\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eNabil Adra, MD\u003c\/strong\u003e\u003cbr\u003eIndiana University Health Melvin and Bren Simon Comprehensive Cancer Center\u003cbr\u003e\u003cem\u003eHigh-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications \u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eAxel Heidenreich, MD\u003c\/strong\u003e\u003cbr\u003eUniversity Hospital of Cologne\u003cbr\u003e\u003cem\u003ePrimary Retroperitoneal Lymph Node Dissection in Stage II Seminoma: Management Strategies and Current Controversies\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eDarren R. Feldman, MD\u003c\/strong\u003e\u003cbr\u003eMemorial Sloan Kettering Cancer Center\u003cbr\u003e\u003cem\u003eLandscape of New Trials and Targets in Refractory Germ Cell Tumors \u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer \u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12:45 PM-2:00 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eThe ABCs of ADCs: Unleashing the Power of Antibody-Drug Conjugates in Advanced Bladder Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eKent William Mouw, MD, PhD—Chair\u003c\/strong\u003e\u003cbr\u003eDana-Farber Cancer Institute, Brigham and Women’s Hospital\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eBenjamin Garmezy, MD—Chair\u003c\/strong\u003e\u003cbr\u003eSarah Cannon Research Institute\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eDi Maria Jiang, MD, MSc, FRCPC\u003c\/strong\u003e\u003cbr\u003ePrincess Margaret Hospital, University Health Network\u003cbr\u003e\u003cem\u003eTargeting Bladder Cancer With Antibody Drug Conjugates\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eFunda Meric-Bernstam, MD, FASCO\u003c\/strong\u003e\u003cbr\u003eUniversity of Texas MD Anderson Cancer Center\u003cbr\u003e\u003cem\u003eHER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eDaniel Castellano, MD\u003c\/strong\u003e\u003cbr\u003eServicio de Oncología Médica, Hospital Universitario 12 de Octubre\u003cbr\u003e\u003cem\u003eOvercoming Challenges of Antibody-Drug Conjugate Toxicity in Bladder Cancer\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eTerence W. Friedlander, MD\u003c\/strong\u003e\u003cbr\u003eUniversity of California, San Francisco Medical Center\u003cbr\u003e\u003cem\u003eBetter Together? Exploring Novel Drug Combinations With Antibody-Drug Conjugates\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 657:\u003c\/strong\u003e Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.\u003cbr\u003eFirst Author: \u003cstrong\u003eBixia Tang, MD, PhD\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2:00 PM-2:30 PM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBreak\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2:30 PM-3:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePanning for Gold: The Role of ctDNA as a Biomarker for Bladder Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eBernadett Szabados, MBBS—Chair\u003c\/strong\u003e\u003cbr\u003eBarts Cancer Centre\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eJoaquim Bellmunt, MD—Chair\u003c\/strong\u003e\u003cbr\u003eDana-Farber Cancer Institute\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eRoger Li, MD\u003c\/strong\u003e\u003cbr\u003eH. Lee Moffitt Cancer Center and Research Institute\u003cbr\u003e\u003cem\u003eCapturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eAlexander William Wyatt, PhD\u003c\/strong\u003e\u003cbr\u003eVancouver Prostate Centre, University of British Columbia\u003cbr\u003e\u003cem\u003eEvolution of Ctdna Detection with Next Generation Technology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eNimira S. Alimohamed, FRCPC\u003c\/strong\u003e\n\u003cbr\u003e\u003cspan lang=\"en-AS\" xml:lang=\"en-AS\"\u003eArthur Child Comprehensive Cancer Centre, University of Calgary\u003c\/span\u003e\n\u003cbr\u003e\u003cem\u003ePotential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eGillian Vandekerkhove, PhD, MSc\u003c\/strong\u003e\u003cbr\u003eVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia\u003cbr\u003e\u003cem\u003eBeneath the Surface: Unleashing the Potential of Ctdna across the Spectrum of Urothelial Carcinoma\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4:00 PM-4:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRapid Oral Abstract Session B: Urothelial Carcinoma\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eKatie S. Murray, DO, FACS, MS—Chair\u003c\/strong\u003e\u003cbr\u003eDepartment of Urology, NYU Langone Health\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eABSTRACT 662:\u003c\/strong\u003e A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with \u003cem\u003eFGFR3 \u003c\/em\u003ealterations: Initial results from FORAGER-1.\u003cbr\u003eFirst Author: \u003cstrong\u003eGopa Iyer, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 663:\u003c\/strong\u003e Datopotamab deruxtecan (Dato-DXd) in locally advanced\/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.\u003cbr\u003eFirst Author: \u003cstrong\u003eFunda Meric-Bernstam, MD, FASCO\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 664\u003c\/strong\u003e: EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC).\u003cbr\u003eFirst Author: \u003cstrong\u003eThomas Powles, MD, PhD, FCRP\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 666\u003c\/strong\u003e: Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.\u003cbr\u003eFirst Author: \u003cstrong\u003eAlina Basnet, MD, MBBS\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 667: \u003c\/strong\u003eA phase 1\/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).\u003cbr\u003eFirst Author: \u003cstrong\u003eNoah M. Hahn, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 815\u003c\/strong\u003e: A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).\u003cbr\u003eFirst Author: \u003cstrong\u003ePooja Ghatalia, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4:45 PM-5:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePoster Session B (Continued)\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Wine and Cheese Reception\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4:45 PM-5:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTrials in Progress Poster Session B (Continued)\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Wine and Cheese Reception\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5:00 PM-5:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePoster Walks: Urothelial Carcinoma\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eElias Chandran, FRACP, MBBS\u003c\/strong\u003e\u003cbr\u003eNational Cancer Institute\u003cbr\u003e\u003cem\u003ePoster Walk Leader\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eArmine Smith, MD\u003c\/strong\u003e\u003cbr\u003eJohns Hopkins University School of Medicine\u003cbr\u003e\u003cem\u003ePoster Walk Leader\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003cbr\u003e\n\u003c\/table\u003e\n\u003ch3\u003eSaturday, February 15, 2025\u003c\/h3\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:00 AM-8:10 AM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eComplimentary Continental Breakfast\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:10 AM-8:10 AM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePoster Session C: Renal Cell Cancer;\u003c\/strong\u003e \u003cstrong\u003eAdrenal, Penile, Testicular and Urethral Cancers\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7:10 AM-8:10 AM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eTrials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8:10 AM-9:45 AM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOral Abstract Session C: Renal Cell Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eArpita Desai, MD—Chair\u003c\/strong\u003e\u003cbr\u003eUniversity of California, San Francisco\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eDaniel Shapiro—Chair\u003c\/strong\u003e\u003cbr\u003eUniversity of Wisconsin-Madison\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTodd Matthew Morgan, MD\u003c\/strong\u003e\u003cbr\u003eWelcome of the Day\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eABSTRACT 438:\u003c\/strong\u003e Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.\u003cbr\u003eFirst Author: \u003cstrong\u003eLaurence Albiges, MD, PhD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 439: \u003c\/strong\u003eNivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.\u003cbr\u003eFirst Author: \u003cstrong\u003eRobert J. Motzer, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 440:\u003c\/strong\u003e KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).\u003cbr\u003eFirst Author: \u003cstrong\u003eKaty Beckermann, MD, PhD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTian Zhang, MD, MHS\u003c\/strong\u003e\u003cbr\u003eUT Southwestern University\u003cbr\u003e\u003cem\u003eDiscussion\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 618:\u003c\/strong\u003e Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.\u003cbr\u003eFirst Author: \u003cstrong\u003eAxel Heidenreich, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eClint Cary, MD, MBA, MPH\u003c\/strong\u003e\u003cbr\u003eIndiana University Simon Comprehensive Cancer Center\u003cbr\u003e\u003cem\u003eDiscussion\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9:45 AM-10:15 AM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBreak\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10:15 AM-11:30 AM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eBiomarkers and Adjuvant Therapy for Renal Cell Carcinoma: Current State and Future Directions\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eShuchi Gulati, MD, MS, FACP—Chair\u003c\/strong\u003e\u003cbr\u003eUniversity of California, Davis Comprehensive Cancer Center\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eAxel Bex, MD, PhD—Chair\u003c\/strong\u003e\u003cbr\u003eRoyal Free London NHS Foundation Trust\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eABSTRACT 437:\u003c\/strong\u003e Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.\u003cbr\u003eFirst Author:\u003cstrong\u003e Wenxin Xu, MD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eSimpa Samuel Salami, MD, MPH\u003c\/strong\u003e\u003cbr\u003eUniversity of Michigan\u003cbr\u003e\u003cem\u003eBiomarkers in Renal Cell Carcinoma: Dead End or Turning Point?\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eSamra Turajlic, MD, PhD\u003c\/strong\u003e\u003cbr\u003eThe Francis Crick Institute\u003cbr\u003e\u003cem\u003eThe Future of Biomarkers in Renal Cell Carcinoma\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eLaurence Albiges, MD, PhD\u003c\/strong\u003e\u003cbr\u003eGustave Roussy, Université Paris Saclay\u003cbr\u003e\u003cem\u003eAdjuvant Therapy in Renal Cell Cancer: A Practical Guide\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:30 AM-12:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePoster Session C (Continued)\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Boxed Lunch\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:30 AM-12:45 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTrials in Progress Poster Session C (Continued)\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003eWith Complimentary Boxed Lunch\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:40 AM-12:35 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eWomen in Genitourinary Cancers Networking Luncheon\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eView the networking faculty list\u003cstrong\u003e \u003cem\u003e\u003ca data-entity-substitution=\"canonical\" data-entity-type=\"node\" data-entity-uuid=\"86e3556e-09bd-46aa-ac12-97b30b57a775\" href=\"https:\/\/conferences.asco.org\/gu\/onsite-connections\" title=\"Onsite Connections\"\u003ehere\u003c\/a\u003e\u003c\/em\u003e\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11:45 AM-12:30 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003ePoster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eBrittney Cotta, MD\u003c\/strong\u003e\u003cbr\u003eUniversity of Texas MD Anderson Cancer Center\u003cbr\u003e\u003cem\u003ePoster Walk Leader\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eShuchi Gulati, MD, FACP, MS\u003c\/strong\u003e\u003cbr\u003eUC Davis Comprehensive Cancer Center\u003cbr\u003e\u003cem\u003ePoster Walk Leader\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12:45 PM-\u003cbr\u003e​​​​​​​1:30 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRapid Oral Abstract Session C: Renal Cell Cancer\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eBrittney Cotta, MD—Chair\u003c\/strong\u003e\u003cbr\u003eUniversity of Texas MD Anderson Cancer Center\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eABSTRACT 441: \u003c\/strong\u003eCasdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.\u003cbr\u003eFirst Author: T\u003cstrong\u003eoni K. Choueiri, MD, FASCO\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 442:\u003c\/strong\u003e Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191).\u003cbr\u003eFirst Author: \u003cstrong\u003eXiaofan Lu, PhD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 443:\u003c\/strong\u003e Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.\u003cbr\u003eFirst Author: \u003cstrong\u003eWen Kong, PhD\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 444:\u003c\/strong\u003e Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).\u003cbr\u003eFirst Author: \u003cstrong\u003eFrancesca Jackson-Spence, MBChB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eABSTRACT 1:\u003c\/strong\u003e EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.\u003cbr\u003eFirst Author: \u003cstrong\u003eAmit Bahl, MD, FRCP, FRCR\u003c\/strong\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1:45 PM-3:00 PM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eCase-Based Session: Failure of Immunotherapy in Renal Cell Cancer: What’s Next?\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eLeslie K. Ballas, MD—Chair\u003c\/strong\u003e\u003cbr\u003eCedars-Sinai Medical Center\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eKathryn Hacker Gessner, MD, PhD—Chair\u003c\/strong\u003e\u003cbr\u003eUNC School of Medicine\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eMaria T. Bourlon, MD, MSc, FASCO\u003c\/strong\u003e\u003cbr\u003eInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán\u003cbr\u003e\u003cem\u003eMedical Oncology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eMatthew T Campbell, MD, MS\u003c\/strong\u003e\u003cbr\u003eThe University of Texas MD Anderson Cancer Center\u003cbr\u003e\u003cem\u003eMedical Oncology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eRaquibul Hannan, MD, PhD\u003c\/strong\u003e\u003cbr\u003eUniversity of Texas Southwestern Medical Center\u003cbr\u003e\u003cem\u003eRadiation Oncology\u003c\/em\u003e\n\u003cbr\u003e\u003cstrong\u003eViraj A. Master, MD, PhD\u003c\/strong\u003e\u003cbr\u003eEmory School of Medicine\u003cbr\u003e\u003cem\u003eUrology\u003c\/em\u003e\n\u003cbr\u003e\u003cem\u003ePanel Question and Answer\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003cbr\u003e\n\u003c\/table\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954475667554,"sku":"MED-AMB04123","price":160.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/ASCO-Genitourinary-Cancers-Symposium-2025-Videos-Slides-Posters.jpg?v=1779377457","url":"https:\/\/meducourse.com\/products\/asco-genitourinary-cancers-symposium","provider":"Meducourse","version":"1.0","type":"link"}